RxDoctor Payments Data

Alberto Lopez, MD

Clinical Cardiac Electrophysiology · Houston, TXNPI 1356364244

Payments from drug & device makers

$10,515in general payments, 2019–2025

Across 395 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$2K
  • Johnson & Johnson$1K
  • Novartis$703
  • Pfizer$537
  • Novo Nordisk$465
  • plus $4K from 27 others

What the payments were for

  • Consulting fees$3,48233%
  • Food & beverage$6,86065%
  • Education$1732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,515 in reported general payments places this provider in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$1,575,733
Medicare patients
749
Services billed
4,847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban187$248,729
XareltoRivaroxaban72$102,142
MultaqDronedarone Hcl16$19,083
Metoprolol Succinate130$2,814
Amiodarone Hcl159$2,636
Flecainide Acetate41$1,754
Atorvastatin Calcium113$1,664
Valsartan19$1,228
Rosuvastatin Calcium82$1,216
Losartan Potassium46$1,074
Carvedilol101$838
Ezetimibe32$794
SotalolSotalol Hcl37$743
Spironolactone48$699
Bisoprolol Fumarate24$691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$537$248,729187 claims
Johnson & JohnsonXarelto$1,196$102,14272 claims
Sanofi-aventis U.S. LLCMultaq$203$19,08316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →